Unfortunately, we are paying the price of "associating" ourselves with DNDN.
The problem with DNDN treatment is that it only marginally increases life expectancy, is expensive but most of all is really complicated to administer...
US investors seem to be looking at other technologies to treat prostate cancer may have just found the next and better DNDN:
http://www.investorplace.com/2011/11/medivation-mdvn-shares-prostate-cancer-treatment-results/
DNDN got hammered, down 37% last night and the reaction was exacerbated by MDVN success (people jumping ships?) I believe in PRR but I will reconsider my position once we get more news flow from Dubai regarding sales, ease of treatment administration...
Good luck to all.
Unfortunately, we are paying the price of "associating"...
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
29.5¢ |
Change
0.005(1.72%) |
Mkt cap ! $428.5M | |||
| Open | High | Low | Value | Volume |
| 28.5¢ | 30.5¢ | 28.5¢ | $469.8K | 1.579M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 9 | 297652 | 29.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 30.0¢ | 7500 | 2 |
View Market Depth
| Last trade - 16.10pm 19/07/2024 (20 minute delay) ? |
| IMM (ASX) Chart |